Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 18/20 | 0.34 |
| ▸ | AKT2 | P31751 | 18/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10287290 | 0.89 | AKT1 (0.42) | AKT1AKT2 | |
| SCHEMBL239678 | 0.89 | AKT1 (0.36) | AKT1AKT2RPS6KB2 | |
| SCHEMBL239679 | 0.89 | AKT1 (0.36) | AKT1AKT2RPS6KB2 | |
| SCHEMBL2755160 | 0.89 | AKT1 (0.36) | AKT1AKT2RPS6KB2 | |
| SCHEMBL239623 | 0.78 | CYP1A2 (0.32) | MEN1USP2ALDH1A1CYP1A2GLA | |
| SCHEMBL2755378 | 0.78 | CYP1A2 (0.32) | MEN1USP2ALDH1A1CYP1A2GLA | |
| SCHEMBL239624 | 0.78 | CYP1A2 (0.32) | MEN1USP2ALDH1A1CYP1A2GLA | |
| SCHEMBL238544 | 0.78 | AKT1 (0.44) | AKT1AKT2 | |
| SCHEMBL238545 | 0.78 | AKT1 (0.44) | AKT1AKT2 | |
| SCHEMBL2755372 | 0.78 | AKT1 (0.44) | AKT1AKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004240-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME LLC | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004240-A1 | INHIBITORS OF AKT ACTIVITY | PIK3CD, PIK3CA, PIK3R5 | AKT1 13/4885AKT2 4/4885MEN1 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.